Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIB Cervical Cancer FIGO 2018: full-pipeline trial registry
1 of 2 indexed Stage IIIB Cervical Cancer FIGO 2018 trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Stage IIIB Cervical Cancer FIGO 2018: 2 US clinical trials tracked, 1 recruiting.
Stage IIIB Cervical Cancer FIGO 2018 is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 1 of these trials.
Enrollment posture brief
Registry condition stage-iiib-cervical-cancer-figo-2018
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Stage IIIB Cervical Cancer FIGO 2018 lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIB Cervical Cancer FIGO 2018 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIB Cervical Cancer FIGO 2018 is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI)
NCT07061977
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
M.D. Anderson Cancer Center
NCT04580771
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIB Cervical Cancer FIGO 2018 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIB Cervical Cancer FIGO 2018 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIB Cervical Cancer FIGO 2018 page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage IIIB Cervical Cancer FIGO 2018 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage IIIB Cervical Cancer FIGO 2018 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIB Cervical Cancer FIGO 2018 condition card totals 2 registered trials; most-linked intervention Cisplatin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.